The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response
Open accessAbstract
BACKGROUND: Achievement of a sustained virologic response (SVR) after treatment for Hepatitis C infection is associated with improved outcomes. This meta-analysis aimed to determine the impact of SVR on long-term mortality risk compared with nonresponders in a range of populations. METHODS: An electronic search identified all studies assessing all-cause mortality in SVR and non-SVR patients. Eligible articles were stratified into general, cirrhotic, and populations coinfected with human immunodeficiency virus. The adjusted hazard ratio (95% confidence interval [CI]) for mortality in patients achieving SVR vs non-SVR, and pooled estimates for the 5-year mortality in each group were calculated. RESULTS: 31 studies (n = 33 360) were identified as suitable for inclusion. Median follow-up time was 5.4 years (interquartile range, 4.9-7.5) across all studies. The adjusted hazard ratio of mortality for patients achieving SVR vs non-SVR was 0.50 (95% CI, .37-.67) in the general population, 0.26 (95% CI, .18-.74) in the cirrhotic group, and 0.21 (.10-.45) in the coinfected group. The pooled 5-year mortality rates were significantly lower for patients achieving SVR compared with non-SVR in all 3 populations. CONCLUSIONS: The results suggest that there is a significant survival benefit of achieving an SVR compared with unsuccessful treatment in a range of populations infected with hepatitis C virus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
Assessing Bias in Studies of Prognostic Factors
Hayden, J. A., van der Windt, D. A., Cartwright, J. L., Côté, P., & Bombardier, C. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-4-201302190-00009 · Cited by 3,287
Mohd Hanafiah, K., Groeger, J., Flaxman, A. D., & Wiersma, S. T. (2013) · Hepatology · doi:10.1002/hep.26141 · Cited by 2,515
van der Meer, A. J., Veldt, B. J., Feld, J. J., Wedemeyer, H., Dufour, J.-F., Lammert, F., Duarte-Rojo, A., Heathcote, E. J., Manns, M. P., Kuske, L., et al. (2012) · JAMA · doi:10.1001/jama.2012.144878 · Cited by 1,510
Thein, H., Yi, Q., Dore, G. J., & Krahn, M. D. (2008) · Hepatology · doi:10.1002/hep.22375 · Cited by 829
Understanding controlled trials: Why are randomised controlled trials important?
Sibbald, B., & Roland, M. (1998) · BMJ · doi:10.1136/bmj.316.7126.201 · Cited by 807
Bruno, S., Stroffolini, T., Colombo, M., Bollani, S., Benvegnù, L., Mazzella, G., Ascione, A., Santantonio, T., Piccinino, F., Andreone, P., et al. (2007) · Hepatology · doi:10.1002/hep.21492 · Cited by 604
A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis C
Backus, L. I., Boothroyd, D. B., Phillips, B. R., Belperio, P., Halloran, J., & Mole, L. A. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.004 · Cited by 481
Outcome of Sustained Virological Responders With Histologically Advanced Chronic Hepatitis C†,‡,§,¶
Morgan, T. R., Ghany, M. G., Kim, H.-Y., Snow, K. K., Shiffman, M. L., De Santo, J. L., Lee, W. M., Di Bisceglie, A. M., Bonkovsky, H. L., Dienstag, J. L., et al. (2010) · Hepatology · doi:10.1002/hep.23744 · Cited by 479
Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon
Di Bisceglie, A. M., Shiffman, M. L., Everson, G. T., Lindsay, K. L., Everhart, J. E., Wright, E. C., Lee, W. M., Lok, A. S., Bonkovsky, H. L., Morgan, T. R., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707615 · Cited by 465
George, S. L., Bacon, B. R., Brunt, E. M., Mihindukulasuriya, K. L., Hoffmann, J., & Di Bisceglie, A. M. (2009) · Hepatology · doi:10.1002/hep.22694 · Cited by 399
Brief Communication: The Relationship of Regression of Cirrhosis to Outcome in Chronic Hepatitis C
Mallet, V., Gilgenkrantz, H., Serpaggi, J., Verkarre, V., Vallet-Pichard, A., Fontaine, H., & Pol, S. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-6-200809160-00006 · Cited by 299
Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C†
Arase, Y., Suzuki, F., Suzuki, Y., Akuta, N., Kobayashi, M., Kawamura, Y., Yatsuji, H., Sezaki, H., Hosaka, T., Hirakawa, M., et al. (2009) · Hepatology · doi:10.1002/hep.22703 · Cited by 265
Pearlman, B. L., & Traub, N. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir076 · Cited by 261
Interferon therapy prolonged life expectancy among chronic hepatitis C patients
Yoshida, H., Arakawa, Y., Sata, M., Nishiguchi, S., Yano, M., Fujiyama, S., Yamada, G., Yokosuka, O., Shiratori, Y., & Omata, M. (2002) · Gastroenterology · doi:10.1053/gast.2002.34785 · Cited by 235
Aleman, S., Rahbin, N., Weiland, O., Davidsdottir, L., Hedenstierna, M., Rose, N., Verbaan, H., Stål, P., Carlsson, T., Norrgren, H., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit234 · Cited by 233
Chen, T., Ding, E. L., Seage III, G. R., & Kim, A. Y. (2009) · Clinical Infectious Diseases · doi:10.1086/644771 · Cited by 224
Limketkai, B. N., Mehta, S. H., Sutcliffe, C. G., Higgins, Y. M., Torbenson, M. S., Brinkley, S. C., Moore, R. D., Thomas, D. L., & Sulkowski, M. S. (2012) · JAMA · doi:10.1001/jama.2012.7844 · Cited by 202
Veldt, B. J., Saracco, G., Boyer, N., Cammà, C., Bellobuono, A., Hopf, U., Castillo, I., Weiland, O., Nevens, F., Hansen, B. E., et al. (2004) · Gut · doi:10.1136/gut.2003.038257 · Cited by 174
El‐Kamary, S. S., Jhaveri, R. R., & Shardell, M. D. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir306 · Cited by 149
The impact of hepatitis C burden: an evidence‐based approach
Younossi, Z. M., Kanwal, F., Saab, S., Brown, K., El‐Serag, H. B., Kim, W. R., Ahmed, A., Kugelmas, M., & Gordon, S. C. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12625 · Cited by 129
Viral hepatitis and the G lobal B urden of D isease: a need to regroup
Cooke, G., Lemoine, M., Thursz, M. R., Gore, C., Swan, T., Kamarulzaman, A., du Cros, P., & Ford, N. P. (2013) · Journal of Viral Hepatitis · doi:10.1111/jvh.12123 · Cited by 122
Self-citationFavorable Prognosis of Chronic Hepatitis C After Interferon Therapy by Long–Term Cohort Study
Imazeki, F., Yokosuka, O., Fukai, K., & Saisho, H. (2003) · Hepatology · doi:10.1053/jhep.2003.50329 · Cited by 100
Braks, R. E. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i42.5648 · Cited by 82
Yau, A. H. L., & Yoshida, E. M. (2014) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2014/549624 · Cited by 76
Kasahara, A., Tanaka, H., Okanoue, T., et al. (2004) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2003.00481.x · Cited by 70
Conjeevaram, H. S., Wahed, A. S., Afdhal, N. H., Howell, C. D., Everhart, J. E., & Hoofnagle, J. H. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.11.002 · Cited by 68
Innes, H. A., Hutchinson, S. J., Allen, S. H., Bhattacharyya, D., Bramley, P. N., Delahooke, T., Dillon, J. F., Forrest, E. H., Fraser, A. G., Gillespie, R. J., et al. (2011) · Hepatology · doi:10.1002/hep.24561 · Cited by 58
Is there sufficient evidence to recommend antiviral therapy in hepatitis C?
van der Meer, A. J., Wedemeyer, H. H., Feld, J. J., Hansen, B. E., Manns, M. P., Zeuzem, S., & Janssen, H. L. A. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.07.043 · Cited by 47
Dieperink, E. W., Pocha, C., THURAS, P. D., Knott, A., Colton, S., & Ho, S. B. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3050-5 · Cited by 44
Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C
Koretz, R. L., Pleguezuelo, M., Arvaniti, V., Barrera, P., Ciria, R., Gurusamy, K. S., Davidson, B. R., & Burroughs, A. K. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003617.pub2 · Cited by 42
Martino, V. D., Crouzet, J., Hillon, P., Thévenot, T., Minello, A., & Monnet, É. (2011) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2011.01476.x · Cited by 25
Patient-important benefits of clearing the hepatitis C virus through treatment: A simulation model
Innes, H. A., Goldberg, D. J., Dusheiko, G. M., Hayes, P. C., Mills, P. R., Dillon, J. F., Aspinall, E., Barclay, S. T., & Hutchinson, S. J. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.020 · Cited by 18
Cozen, M. L., Ryan, J. C., Shen, H., Lerrigo, R., Yee, R. M., Sheen, E., Wu, R., & Monto, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061568 · Cited by 16
Long‐term follow up of chronic hepatitis C patients after α‐interferon treatment: A functional study
Giannini, E. G., Fasoli, A., Botta, F., Testa, E., Romagnoli, P., Ceppa, P., & Testa, R. (2001) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2001.02463.x · Cited by 10
Singal, A. G., Dharia, T., Malet, P. F., Alqahtani, S. A., Zhang, S., & Cuthbert, J. A. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003231 · Cited by 8
Cited by
Stanaway, J. D., Flaxman, A. D., Naghavi, M., Fitzmaurice, C., Vos, T., Abubakar, I., Abu-Raddad, L. J., Assadi, R., Bhala, N., Cowie, B., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30579-7 · Cited by 1,358
Self-citationGhany, M. G., Morgan, T. R., & Panel, A. H. C. G. (2020) · Hepatology · doi:10.1002/hep.31060 · Cited by 955
Carrat, F., Fontaine, H., Dorival, C., Simony, M., Diallo, A., Hezode, C., De Ledinghen, V., Larrey, D., Haour, G., Bronowicki, J.-P., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32111-1 · Cited by 628
Woodward, E. N., Matthieu, M. M., Uchendu, U. S., Rogal, S., & Kirchner, J. E. (2019) · Implementation Science · doi:10.1186/s13012-019-0861-y · Cited by 470
Simmons, B., Saleem, J., Hill, A., Riley, R. D., & Cooke, G. S. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ948 · Cited by 314
Self-citation
Metadata
- Authors
- Simmons, B., Saleem, J., Heath, K., Cooke, G. S., & Hill, A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-05-17
- Volume
- 61
- Issue
- 5
- Pages
- 730-740
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2170706646
- Cited by
- 261
- References
- 38
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.